Encore Presentations
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Objectives: Aging with HIV has unique challenges, including comorbidities and drug-drug interactions. TANDEM was a retrospective medical chart review conducted across 24 US sites. This subgroup analysis examines stable-switch PLWH receiving dolutegravir/lamivudine by age.
Methods: Eligible PLWH were adults initiating dolutegravir/lamivudine prior to Sept/30/2020 with =6 months clinical follow-up. Stable-switch PLWH were defined as having HIV-1 RNA <50 copies/mL and on a stable antiretroviral regimen for =3 months upon dolutegravir/lamivudine initiation. Clinical characteristics, treatment history, and outcomes were analyzed for 3 age groups among dolutegravir/lamivudine stable-switch PLWH. Analyses were descriptive.
Results: The number of dolutegravir/lamivudine stable-switch PLWH in each age group was 86 (<50 years), 106 (=50 years), and 20 (=65 years). A greater proportion of PLWH in the older age groups were female sex at birth (14.0% <50 years; 20.8% =50 years; 30.0% =65 years). More PLWH in older age groups had reported comorbidity (12.8% <50 years; 34.9% =50 years; 45.0% =65 years) and polypharmacy (5.8% <50 years; 17.9% =50 years; 30.0% =65 years). Avoidance of long-term toxicities was the biggest driver for initiating dolutegravir/lamivudine in the older age groups (32.1% =50 years; 30.0% =65 years) while simplification/streamlining of treatment was the most common (27.9%) primary reason for PLWH to switch to dolutegravir/lamivudine in the <50 years group. For PLWH <50 years, 95.3% remained virologically suppressed for the study period. Similarly, 96.2% of PLWH =50 years and 95.0% of PLWH =65 years remained virologically suppressed for the study period. Three patients with NRTI resistance at baseline remained suppressed.
Conclusions: Virological suppression rates were high and similar by age group among dolutegravir/lamivudine stable-switch PLWH despite higher rates of comorbidities and polypharmacy in the older age groups. This real-world analysis is consistent with clinical study data supporting dolutegravir/lamivudine as an effective treatment strategy in older PLWH.
Published citation: Brogan A, Slim J, Verdier G, et al. Virological suppression in people living with HIV-1 (PLWH) receiving dolutegravir/lamivudine was high and similar across age groups despite older PLWH having increased rates of comorbidities and polypharmacy (TANDEM SUBGROUP) [abstract SA49]. Value Health. 2023;26(6 suppl):S406.
Presenting Author
Kristen Fuhrmann Pharm.D.ViiV Healthcare
Authors
Andrew Brogan PhD
ViiV Healthcare
Gavin Harper BA
Gabrielle Herman PharmD, BCIDP, AAHIVP
ViiV Healthcare
Katie Mycock MChem
Cynthia Donovan PharmD
ViiV Healthcare
Gustavo Verdier BSc
Hannah Wallis MS
Jihad Slim MD
Saint Michael’s Medical Center